AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

4 stories found

Six protein biomarker dials converge on an experimental molecule above a lung scan while an unfinished trial path continues into shadow.
Social good & healthGlobal+2 clusters01

An AI-discovered lung drug shifted six aging clocks, not human lifespan

An experimental drug developed with AI has produced a result that is scientifically interesting and extremely easy to oversell. Rentosertib was designed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. Its target was identified with AI and its molecule was generated through an AI-driven discovery platform. Researchers analyzed protein data from 42 patients in a 12-week phase 2a trial and applied six independently developed proteomic aging clocks. All six estimated a reduction in predicted biological age among treated patients. Earlier trial results also showed a promising dose-related improvement in forced vital capacity, an important lung-function measure. Agreement across multiple clocks makes the signal less likely to be an artifact of one aging model. It does not prove that the drug extends life, reverses aging throughout the body, or is safe and effective as a longevity treatment. The cohort was small, the follow-up was short, the participants had a serious age-related disease, and improving inflammation or fibrosis can change proteins used by aging clocks. The Nature Biotechnology paper also discloses that several authors work for the company developing the drug and that its company leader is an author. The responsible interpretation is neither miracle nor dismissal. This is a hypothesis-generating biomarker result attached to a candidate that has advanced in clinical development. Larger, longer, independently scrutinized trials should prespecify aging endpoints and connect them with functional outcomes, safety, disease progression, and eventually survival. AI accelerated the discovery path. Biology still decides whether the claim survives.

5 min
A precise national-policy dossier shows AI benefits passing through signed safety, worker-support, and human-control checkpoints before a scale gate opens.
Law & informationSingapore+4 clusters02

Singapore puts human control at the center of national AI adoption

Singapore’s 2026 National Day Rally framed AI adoption as a national bargain rather than an unrestricted technology race. The prime minister highlighted AI agents for small businesses, personalized exercise plans, breast-cancer screening support, genomics, and autonomous-vehicle trials. He also said adoption should not run ahead of the country’s ability to retrain and support affected workers, that autonomous vehicles should scale only after safety is proven, and that people must remain in control as capable agents create harder-to-predict risks. The speech committed Singapore to practical safeguards at home and coalitions for international rules, while stopping short of specifying every enforcement mechanism or timetable. The value of the approach is its sequence: prove the system, govern the risk, support the people disrupted, then scale. That standard now needs measurable implementation through named regulators, published stop conditions, worker outcomes, incident disclosure, and public evidence that human control is operational rather than ceremonial.

5 min
A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters03

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
A clinical waveform and reinforcement-learning decision tree ending at an evidence gap.
Cognition & learningGlobal+2 clusters04

Tang et al., “Reinforcement learning for treatment decision-making in sepsis: a scoping review”

Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.

2 min